Research Analysts Issue Forecasts for NBIX FY2026 Earnings

Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Neurocrine Biosciences in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer forecasts that the company will earn $6.53 per share for the year. The consensus estimate for Neurocrine Biosciences' current full-year earnings is $4.28 per share.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a return on equity of 13.38% and a net margin of 14.49%. The business had revenue of $572.60 million for the quarter, compared to analyst estimates of $587.06 million. Neurocrine Biosciences's quarterly revenue was up 11.1% on a year-over-year basis. During the same period last year, the firm posted $1.20 EPS.

NBIX has been the topic of a number of other research reports. BMO Capital Markets boosted their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the stock a "market perform" rating in a research note on Tuesday, May 6th. JPMorgan Chase & Co. increased their target price on shares of Neurocrine Biosciences from $183.00 to $184.00 and gave the company an "overweight" rating in a research report on Wednesday, March 26th. Evercore ISI decreased their price target on Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. UBS Group raised their target price on Neurocrine Biosciences from $137.00 to $152.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Finally, Royal Bank of Canada reiterated an "outperform" rating and issued a $145.00 target price on shares of Neurocrine Biosciences in a report on Monday, June 2nd. Three research analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Trading Down 0.5%

NASDAQ NBIX traded down $0.62 during trading on Tuesday, hitting $124.39. 775,176 shares of the company's stock were exchanged, compared to its average volume of 1,142,687. The company has a market cap of $12.31 billion, a PE ratio of 37.81, a P/E/G ratio of 0.77 and a beta of 0.24. Neurocrine Biosciences has a fifty-two week low of $84.23 and a fifty-two week high of $157.98. The stock's 50 day moving average price is $112.39 and its two-hundred day moving average price is $121.93.

Neurocrine Biosciences announced that its Board of Directors has initiated a stock buyback plan on Friday, February 21st that permits the company to repurchase $500.00 million in outstanding shares. This repurchase authorization permits the company to purchase up to 4.2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board of directors believes its stock is undervalued.

Insider Activity

In other news, Director William H. Rastetter sold 30,000 shares of the company's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $110.20, for a total value of $3,306,000.00. Following the completion of the sale, the director now owns 37,491 shares in the company, valued at $4,131,508.20. This represents a 44.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Kevin Charles Gorman sold 9,613 shares of the stock in a transaction dated Tuesday, May 27th. The shares were sold at an average price of $120.38, for a total transaction of $1,157,212.94. Following the completion of the sale, the director now owns 514,596 shares of the company's stock, valued at approximately $61,947,066.48. This represents a 1.83% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company's stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Institutional investors have recently added to or reduced their stakes in the company. Golden State Wealth Management LLC bought a new position in shares of Neurocrine Biosciences in the fourth quarter valued at approximately $25,000. Geneos Wealth Management Inc. boosted its position in Neurocrine Biosciences by 143.6% in the first quarter. Geneos Wealth Management Inc. now owns 229 shares of the company's stock worth $25,000 after purchasing an additional 135 shares during the last quarter. Huntington National Bank grew its stake in Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock valued at $31,000 after purchasing an additional 97 shares during the period. WPG Advisers LLC purchased a new stake in shares of Neurocrine Biosciences during the 1st quarter valued at $32,000. Finally, Smallwood Wealth Investment Management LLC bought a new stake in Neurocrine Biosciences in the first quarter worth about $34,000. 92.59% of the stock is owned by institutional investors.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.